Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia

Sponsor
University of Virginia (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05660525
Collaborator
(none)
768
32
60

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to evaluate the effectiveness and implementation of a pharmacist-delivered MTM (medication therapy management) approach, called QuitAid, to quitting cigarette smoking in rural Appalachia.

The main questions it aims to answer are:
  • Is QuitAid, alone or combined with other quitting tobacco treatments, effective?

  • What makes QuitAid easy or hard to carry out? Is it cost effective? Is it easy to maintain?

Treatment:

All participants will be given at least 4 weeks of the nicotine patch.

Some participants will be randomized (like the flip of a coin) to receive additional treatments (listed below).

These groups will be compared to each other to see which combination works best to help them quit smoking.

  • Smokefree TXT - a texting program that helps people quit smoking

  • Tobacco quitline - 4 phone sessions to help people quit smoking

  • 8 weeks of NRT (nicotine replacement therapy in the form of nicotine patches or nicotine patches and lozenge) medication instead of 4 weeks

  • QuitAid - An MTM program given by the patient's pharmacist. This is a quitting smoking coaching program

  • Nicotine patch AND nicotine lozenge instead of just nicotine patches

Condition or Disease Intervention/Treatment Phase
  • Drug: 4 weeks of Nicotine lozenge
  • Drug: 8 weeks of Nicotine Replacement Therapy Patch
  • Behavioral: QuitAid
  • Behavioral: Smokefree TXT
  • Behavioral: Tobacco Quitline
  • Drug: 4 weeks of Nicotine Replacement Therapy Patch
  • Drug: 8 Weeks Nicotine Lozenge
N/A

Detailed Description

The proposed study uses a mixed-method design to evaluate the effectiveness and implementation of a pharmacist-delivered MTM (Medication Therapy Management) approach, called QuitAid, to smoking cessation in rural Appalachia. Aim 1 of this project will evaluate the effectiveness of QuitAid and standard, evidence-based tobacco treatments on cessation within an MTM pharmacist-delivered approach. Aim 2 will assess implementation, including relative cost of QuitAid, as well as standard, evidence-based tobacco treatments through an ask-advise-connect model, in community pharmacies, and will examine facilitators and barriers to reach, adoption, and maintenance of QuitAid as well as standard, evidence-based tobacco treatments through an ask-advise-connect method in community pharmacies.

Smokers (n=768) recruited through 14 community pharmacies in rural Appalachia will be randomized in a 2x2x2x2x2 full factorial experiment to the following five treatments: (1) QuitAid Intervention (Yes vs. No), (2) tobacco quitline (Yes vs. No), (3) SmokefreeTXT through the National Cancer Institute's (NCI) Smokefree.gov initiative (Yes vs. No), (4) Combination NRT Lozenge + NRT Patch (vs. NRT patch alone), and/or (5) 8 weeks of NRT (vs. standard 4 weeks). Following the experimental trial, we will use an implementation science approach to assess implementation, including relative cost, as well as facilitators and barriers of reach, adoption, and maintenance of QuitAid and standard, evidence-based tobacco treatments through an ask-advise-connect method in community pharmacies (Aim 2).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
768 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Intervention Model Description:
2x2x2x2x22x2x2x2x2
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2027
Anticipated Study Completion Date :
Mar 1, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: QuitAid, 4 weeks, Patch + Lozenge

Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist and 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and the nicotine lozenge.

Drug: 4 weeks of Nicotine lozenge
All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: QuitAid, 8 weeks, Patch + Lozenge

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist and 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and the nicotine lozenge.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Drug: 8 Weeks Nicotine Lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Experimental: QuitAid, 4 weeks, Patch + Lozenge, QuitLine

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and the nicotine lozenge, and a Quitline intervention

    Drug: 4 weeks of Nicotine lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: QuitAid, 8 weeks, Patch + Lozenge, QuitLine

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and the nicotine lozenge, and a Quitline intervention

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Drug: 8 Weeks Nicotine Lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Experimental: QuitAid, 4 weeks, Patch

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist and 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch.

    Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: QuitAid, 8 weeks, Patch

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist and 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Experimental: QuitAid, 8 weeks, Patch, QuitLine

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a Quitline intervention

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Experimental: QuitAid, 4 weeks, Patch, QuitLine

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a Quitline intervention

    Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: QuitAid, 4 weeks, Patch, SmokeFree Txt

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a texting intervention to help quit smoking.

    Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: QuitAid, 8 weeks, Patch, SmokeFree Txt

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a texting intervention to help quit smoking.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Experimental: QuitAid, 8 weeks, Patch + Lozenge, SmokeFree Txt

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, and a texting intervention to help quit smoking.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Drug: 8 Weeks Nicotine Lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Experimental: QuitAid, 4 weeks, Patch + Lozenge, SmokeFree Txt

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, and a texting intervention to help quit smoking.

    Drug: 4 weeks of Nicotine lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: QuitAid, 8 weeks, Patch + Lozenge, SmokeFree Txt, QuitLine

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, a texting intervention to help quit smoking, and a Quitline Intervention.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Drug: 8 Weeks Nicotine Lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Experimental: QuitAid, 8 weeks, Patch, SmokeFree Txt, QuitLine

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, a texting intervention to help quit smoking, and a Quitline Intervention.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Experimental: QuitAid, 4 weeks, Patch + Lozenge, SmokeFree Txt, QuitLine

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, a texting intervention to help quit smoking, and a Quitline Intervention.

    Drug: 4 weeks of Nicotine lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: QuitAid, 4 weeks, Patch, SmokeFree Txt, QuitLine

    Smoking participants receive QuitAid, a medication therapy management delivered by their pharmacist, 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, a texting intervention to help quit smoking, and a Quitline Intervention.

    Behavioral: QuitAid
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
    Other Names:
  • Medication Therapy Management (MTM)
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: 8 weeks, Patch + Lozenge, SmokeFree Txt, QuitLine

    Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, a texting intervention to help quit smoking, and a Quitline Intervention.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Drug: 8 Weeks Nicotine Lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Experimental: 8 weeks, Patch, SmokeFree Txt, QuitLine

    Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, a texting intervention to help quit smoking, and a Quitline Intervention.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Experimental: 4 weeks, Patch + Lozenge, SmokeFree Txt, QuitLine

    Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, a texting intervention to help quit smoking, and a Quitline Intervention.

    Drug: 4 weeks of Nicotine lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: 4 weeks, Patch, SmokeFree Txt, QuitLine

    Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, a texting intervention to help quit smoking, and a Quitline Intervention.

    Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: 8 weeks, Patch + Lozenge, QuitLine

    Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, and a Quitline Intervention.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Drug: 8 Weeks Nicotine Lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Experimental: 8 weeks, Patch, QuitLine

    Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a Quitline Intervention.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Experimental: 4 weeks, Patch + Lozenge, QuitLine

    Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge, and a Quitline Intervention.

    Drug: 4 weeks of Nicotine lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: 4 weeks, Patch, QuitLine

    Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch, and a Quitline Intervention.

    Behavioral: Tobacco Quitline
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.

    Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: 8 weeks, Patch + Lozenge, SmokeFree Txt

    Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge and a texting intervention to help quit smoking.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Drug: 8 Weeks Nicotine Lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Experimental: 8 weeks, Patch, SmokeFree Txt

    Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and a texting intervention to help quit smoking.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Experimental: 4 weeks, Patch + Lozenge, SmokeFree Txt

    Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge and a texting intervention to help quit smoking.

    Drug: 4 weeks of Nicotine lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: 4 weeks, Patch, SmokeFree Txt

    Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and a texting intervention to help quit smoking.

    Behavioral: Smokefree TXT
    All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.

    Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: 8 weeks, Patch + Lozenge

    Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Drug: 8 Weeks Nicotine Lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Experimental: 8 weeks, Patch

    Smoking participants receive 8 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch.

    Drug: 8 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
    Other Names:
  • Habitrol Transdermal Product
  • Pixotine Transdermal Product
  • Lucy Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Nicotrol Transdermal Product
  • Experimental: 4 weeks, Patch + Lozenge

    Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch and lozenge.

    Drug: 4 weeks of Nicotine lozenge
    All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
    Other Names:
  • Sunmark Nicotine Polacrilex Lozenge
  • Habitrol Nicotine Lozenge
  • Nicotinell Nicotine Lozenge
  • Nicorette Lozenge
  • Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Experimental: 4 weeks, Patch

    Smoking participants receive 4 weeks Nicotine Replacement Therapy (NRT) in the form of the nicotine patch.

    Drug: 4 weeks of Nicotine Replacement Therapy Patch
    All participants will receive at least 4 weeks of the NRT Patch.
    Other Names:
  • Nicotrol Transdermal Product
  • Nicoderm C-Q Transdermal Product
  • Lucy Transdermal Product
  • Pixotine Transdermal Product
  • Habitrol Transdermal Product
  • Outcome Measures

    Primary Outcome Measures

    1. Tobacco Abstinence [6 months]

      The primary outcome is biochemically verified point prevalence abstinence defined as no smoking (even a puff) within the past 7 days.

    Secondary Outcome Measures

    1. Self-Reported Tobacco Abstinence [1, 2, and 3 months]

      Self-reported point prevalence abstinence defined as no smoking (even a puff) within the past 7 days

    2. Adherence to assigned treatment components [1, 2, and 3 months]

      Assess adherence to assigned treatment regimen as the percentage of sessions completed if the participant was assigned to QuitAid and/or the quitline treatments, the frequency of opt-out from SmokefreeTXT (e.g., texting "STOP"), and the percent of NRT used. Adherence to NRT (both patch and/or lozenge) will be collected from participants at the 1-, 2-, and 3-month follow-ups.

    3. Quit Attempts [1, 2, and 3 months]

      Assess the number of times that participants have made a quit attempt since the previous contact at the 1-, 2-, 3- and 6-month follow-ups. A "quit attempt" will be defined as cigarette abstinence for ≥ 24 hours not due to involuntary or forced cessation (i.e., hospitalization)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes

    Study participants will be rural cigarette smokers from Virginia, Tennessee, Kentucky and North Carolina who visit one of the participating study pharmacies. Pharmacies will be located in rural geographic areas of the Central and South Central subregions of Appalachia that include Virginia, Tennessee, Kentucky and North Carolina, as defined by the RUCA codes 4-10. No exclusionary criteria are based on race, gender, or age.

    Inclusion Criteria include:
    • must be 18 years of age and older

    • must be able to read, speak, and understand English

    • must report smoking at least 5 cigarettes per day for the past 6 months (regardless of non-cigarette tobacco product use)

    • must be willing to set a quit date within the next 30 days

    • must own a cell phone

    • must be willing and able to use NRT in the form of patch or lozenge

    • Not be pregnant or planning to be pregnant in the next 6 months.

    Exclusion Criteria include:
    • are pregnant women (self-reported), breastfeeding, planning to become pregnant during the next 6 months

    • have a medical contraindication to NRT (e.g., past 30 days, heart attack or stroke; past 6 months, serious or worsening angina, very rapid or irregular heartbeat requiring medication)

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University of Virginia

    Investigators

    • Principal Investigator: Melissa Little, PhD, MPH, University of Virginia

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Melissa Little, PhD, MPH, Associate Professor, University of Virginia
    ClinicalTrials.gov Identifier:
    NCT05660525
    Other Study ID Numbers:
    • HSR220197
    First Posted:
    Dec 21, 2022
    Last Update Posted:
    Dec 21, 2022
    Last Verified:
    Dec 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 21, 2022